CL2020002876A1 - Infectious Bronchitis Vaccine (Divisional Application No. 201803420) - Google Patents

Infectious Bronchitis Vaccine (Divisional Application No. 201803420)

Info

Publication number
CL2020002876A1
CL2020002876A1 CL2020002876A CL2020002876A CL2020002876A1 CL 2020002876 A1 CL2020002876 A1 CL 2020002876A1 CL 2020002876 A CL2020002876 A CL 2020002876A CL 2020002876 A CL2020002876 A CL 2020002876A CL 2020002876 A1 CL2020002876 A1 CL 2020002876A1
Authority
CL
Chile
Prior art keywords
divisional application
infectious bronchitis
bronchitis vaccine
vaccine
component
Prior art date
Application number
CL2020002876A
Other languages
Spanish (es)
Inventor
Freitas Carla Maria Batista De
Santos Maria Carolina Ferreira Dos
Paul Joseph Dominowski
Harmen Jacob Geerligs
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CL2020002876A1 publication Critical patent/CL2020002876A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/265—Infectious rhinotracheitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Una vacuna que comprende un componente de antígeno y un componente adyuvante, en donde el componente adyuvante comprende un oligonucleótido inmunoestimulante y una emulsión de agua-en-aceite (W/O), donde el componente antigénico comprende un virus IBD inactivado, y donde el oligonucleótido inmunoestimulante comprende la SEQ ID NO: 8 en una cantidad de 2,5 a 20 µg por dosis.A vaccine comprising an antigen component and an adjuvant component, wherein the adjuvant component comprises an immunostimulating oligonucleotide and a water-in-oil (W / O) emulsion, wherein the antigen component comprises an inactivated IBD virus, and where the immunostimulatory oligonucleotide comprises SEQ ID NO: 8 in an amount of 2.5 to 20 µg per dose.

CL2020002876A 2016-06-02 2020-11-06 Infectious Bronchitis Vaccine (Divisional Application No. 201803420) CL2020002876A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662344598P 2016-06-02 2016-06-02
US201662365419P 2016-07-22 2016-07-22

Publications (1)

Publication Number Publication Date
CL2020002876A1 true CL2020002876A1 (en) 2021-05-07

Family

ID=59215993

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2018003420A CL2018003420A1 (en) 2016-06-02 2018-11-30 Vaccine against infectious bronchitis.
CL2020002876A CL2020002876A1 (en) 2016-06-02 2020-11-06 Infectious Bronchitis Vaccine (Divisional Application No. 201803420)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2018003420A CL2018003420A1 (en) 2016-06-02 2018-11-30 Vaccine against infectious bronchitis.

Country Status (15)

Country Link
US (3) US11103573B2 (en)
EP (1) EP3463446A1 (en)
JP (3) JP7659367B2 (en)
KR (6) KR20210068602A (en)
CN (1) CN109152829A (en)
AU (1) AU2017274332B2 (en)
BR (1) BR112018075033A2 (en)
CA (2) CA3025524C (en)
CL (2) CL2018003420A1 (en)
CO (1) CO2018012905A2 (en)
MX (3) MX2018014857A (en)
PH (1) PH12018502525A1 (en)
UA (1) UA126562C2 (en)
WO (1) WO2017210244A1 (en)
ZA (3) ZA201807477B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111303252A (en) * 2020-02-17 2020-06-19 青岛易邦生物工程有限公司 Purification method for large-scale production of embryotoxin antigen
WO2024077025A1 (en) * 2022-10-04 2024-04-11 Zoetis Services Llc Poultry vaccines and methods of protecting poultry

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA978434B (en) * 1996-09-27 1998-03-26 Akzo Nobel Nv Inactivated vaccines.
CA2238659C (en) * 1997-05-26 2010-12-14 Akzo Nobel N.V. Recombinant birnavirus vaccine
US6048535A (en) 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
EP1357151A1 (en) 2002-04-26 2003-10-29 ATOFINA Research Improved processing of bimodal polymers
WO2005063284A1 (en) * 2003-12-23 2005-07-14 Intervet International B.V Combination vaccine for poultry
KR101172921B1 (en) 2004-03-12 2012-08-13 와이어쓰 엘엘씨 Infectious bursal disease virus antigenic isolates and vaccines
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
KR101251707B1 (en) 2006-09-27 2013-04-11 콜리 파마슈티칼 게엠베하 CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity
US8679504B2 (en) * 2008-05-22 2014-03-25 University Of Georgia Research Foundation Inc. Poultry viral materials and methods related thereto
CN102076358B (en) 2008-06-27 2016-08-17 硕腾有限责任公司 Novel adjuvant composition
AR072976A1 (en) 2008-08-08 2010-10-06 Wyeth Corp ISOLATED INFECTIOUS BRONCHITIS (IB) VIRUSES, VACCINE COMPOSITION AND METHOD TO PREPARE AN INFECTIOUS BRONCHITIS (IB) VIRUS ATTACHED LIVE
CN101721698B (en) 2008-10-24 2014-04-02 法罗斯疫苗公司 Anti-foot-and-mouth disease vaccine composition and its preparation and application
MY160201A (en) * 2008-12-09 2017-02-28 Coley Pharm Group Inc Immunostimulatory oligonucleotides
CN102038949A (en) * 2010-12-29 2011-05-04 青岛易邦生物工程有限公司 Method for producing newcastle disease, infectious bronchitis, egg drop syndrome and avian influenza (H9 subtype) combined inactivated vaccine
EP2471926A3 (en) * 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
KR101974382B1 (en) 2011-04-18 2019-05-03 유니버시티 오브 죠지아 리서치 파운데이션, 인코포레이티드 Vaccine delivery method
MX382968B (en) 2012-11-16 2025-03-12 United Biomedical Inc Synthetic peptide-based emergency vaccine against foot and mouth disease (fmd)
DK3542819T3 (en) * 2013-05-14 2021-09-20 Zoetis Services Llc Novel vaccine compositions comprising immunostimulatory oligonucleotides
RU2730011C2 (en) 2013-09-19 2020-08-14 Зоэтис Сервисиз Ллс Oil-based adjuvants

Also Published As

Publication number Publication date
KR20180129926A (en) 2018-12-05
CO2018012905A2 (en) 2018-12-14
AU2017274332B2 (en) 2024-06-27
JP2023002541A (en) 2023-01-10
CA3025524A1 (en) 2017-12-07
EP3463446A1 (en) 2019-04-10
BR112018075033A2 (en) 2019-03-26
KR20210068601A (en) 2021-06-09
KR20220064417A (en) 2022-05-18
ZA201807477B (en) 2023-06-28
CL2018003420A1 (en) 2019-01-18
MX2018014857A (en) 2019-03-07
US20190240315A1 (en) 2019-08-08
JP2025041829A (en) 2025-03-26
US12171825B2 (en) 2024-12-24
AU2017274332A1 (en) 2018-11-22
JP7679340B2 (en) 2025-05-19
NZ788649A (en) 2025-05-30
JP7659367B2 (en) 2025-04-09
WO2017210244A1 (en) 2017-12-07
JP2019517526A (en) 2019-06-24
US20250295752A1 (en) 2025-09-25
ZA202204979B (en) 2022-09-28
KR20220100725A (en) 2022-07-15
RU2018142329A3 (en) 2020-09-01
MX2022007212A (en) 2022-07-12
RU2018142329A (en) 2020-06-01
KR20240141211A (en) 2024-09-25
MX2022012910A (en) 2022-11-14
RU2021117820A (en) 2021-07-07
NZ748375A (en) 2024-07-26
NZ788650A (en) 2025-08-29
ZA202204980B (en) 2022-09-28
KR20210068602A (en) 2021-06-09
KR102893877B1 (en) 2025-12-03
UA126562C2 (en) 2022-11-02
CN109152829A (en) 2019-01-04
CA3025524C (en) 2023-03-07
PH12018502525A1 (en) 2019-10-21
CA3175832A1 (en) 2017-12-07
US20220175911A1 (en) 2022-06-09
US11103573B2 (en) 2021-08-31

Similar Documents

Publication Publication Date Title
Baz et al. H5N1 vaccines in humans
PH12019501766A1 (en) Porcine coronavirus vaccines
AR127585A1 (en) RESPIRATORY SYNCYCIAL VIRUS RNA VACCINE
MX2023000411A (en) Sars-cov-2 and influenza combination vaccine.
TW201612316A (en) Porcine pseudorabies virus gene deletion strain, vaccine composition, and preparation method and application of vaccine composition
CO2019011548A2 (en) Recombinant gallid herpesvirus 3 vaccines encoding heterologous avian pathogenic antigens
MX376715B (en) VACCINE AGAINST SWINE EPIDEMIC DIARRHEA VIRUS.
TW201613558A (en) Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
AR108829A1 (en) VACCINE AGAINST INFECTIOUS BRONCHITIS VIRUS
JOP20190088A1 (en) Recombinant vectors expressing antigens of avian influenza virus and uses thereof
MX388128B (en) COMBINED VACCINE FOR PIGS.
CU24580B1 (en) ATTENUATED VECTORS OF INFLUENZA FOR THE PREVENTION AND/OR TREATMENT OF INFECTIOUS DISEASES AND FOR THE TREATMENT OF ONCOLOGICAL DISEASES
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
BR112015022582A2 (en) nucleic acid molecule, plasmid, vaccine, and use of a plasmid
MX386606B (en) THE USE OF A VACCINE FOR THE PREVENTION OF SWINE EPIDEMIC DIARRHEA.
CL2020002876A1 (en) Infectious Bronchitis Vaccine (Divisional Application No. 201803420)
EA201001478A1 (en) VACCINE
WO2020012428A8 (en) New vaccines against avian reoviruses
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
AR056733A1 (en) USE OF VACCINES FOR THE TREATMENT / PREVENTION OF THE TRANSMISSION OF PATHOGENS
AR097029A1 (en) ACCELERATION OF THE IMMUNE RESPONSE INDUCED BY VECTOR VIRUS IN BIRDS, COMPOSITION, USE, VACCINATION METHOD AND METHOD FOR ACCELERATING THE IMMUNE RESPONSE
PH12022550939A1 (en) Chikungunya virus-like particle vaccine and methods of using the same
MX2020003753A (en) Nasal hepatitis b vaccine composition and method for producing same.
MX2012002630A (en) IMMUNIZATION REGIME FOR SENSITIZATION-REINFORCEMENT HETEROLOGY AGAINST THE BLUE LANGUAGE VIRUS.
PH12020550948A1 (en) Vaccines against hendra and nipah virus infection